Fragile X Syndrome – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Fragile X Syndrome – Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
- The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Acadia Pharmaceuticals IncAdvantx Pharmaceuticals Inc
Aelis Farma SAS
Allos Pharma Inc
Anavex Life Sciences Corp
Anima Biotech Inc
Astellas Pharma Inc
Astrogen Ltd
Autifony Therapeutics Ltd
Avekshan LLC
Baergic Bio Inc
Biomed Industries Inc
Centre National de la Recherche Scientifique
Children's Hospital of Philadelphia
Connecta Therapeutics SL
DRI Biosciences Corp
Epigen Biosciences Inc
Forge Biologics Inc
GEXVal Inc
GSK plc
Halucenex Life Sciences Inc
Healx Ltd
Hua Medicine Shanghai Ltd
Jazz Pharmaceuticals Plc
Kantify
Lenire Biosciences Inc
Lysogene SAS
Marvel Biotechnology Inc
Neuren Pharmaceuticals Ltd
Neurochlore
NeuroNascent Inc
Neuroventi Co Ltd
Nova Mentis BioTech Corp
Novartis AG
Paxmedica Inc
Prilenia Therapeutics Development Ltd
Prime Medicine Inc
Prous Institute for Biomedical Research SA
Puretech Health Plc
Quris Technologies Ltd
Recursion Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc
Sentinel Oncology Ltd
Takeda Pharmaceutical Co Ltd
Taysha Gene Therapies Inc
Tetra Therapeutics
Triplet Therapeutics Inc
University of Calgary
Unravel Biosciences
Yale University School of Medicine
Zynerba Pharmaceuticals Inc